Ryvu Therapeutics SA (RVU)

Currency in PLN
16.00
-0.02(-0.12%)
Closed·
RVU is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.8016.30
52 wk Range
13.6431.90
Key Statistics
Bid/Ask
15.92 / 16.00
Prev. Close
16.02
Open
16.2
Day's Range
15.8-16.3
52 wk Range
13.64-31.9
Volume
29.49K
Average Volume (3m)
48.06K
1-Year Change
-47.3684%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RVU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.62
Upside
+110.12%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Ryvu Therapeutics SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

2 Buy
3 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 33.62
(+110.12% Upside)

Earnings

Latest Release
20/05/2026
EPS / Forecast
-0.55 / --
Revenue / Forecast
21.7M / --
EPS Revisions
Last 90 days

RVU Income Statement

Compare RVU to Peers and Sector

Metrics to compare
RVU
Peers
Sector
Relationship
P/E Ratio
−4.2x−11.8x−0.4x
PEG Ratio
−0.140.010.00
Price/Book
9.0x2.4x2.6x
Price / LTM Sales
4.2x2.3x3.0x
Upside (Analyst Target)
81.0%34.3%51.8%
Fair Value Upside
Unlock20.6%7.2%Unlock

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia. In addition, the company’s early pipeline candidates include candidates in the areas of kinases, synthetic lethality, immunometabolism, and immuno-oncology. It has collaborations with BioNTech SE to advance small molecule programs to target immune modulation in cancer and other disease areas; Exelixis Inc. for the development of targeted therapies based on Ryvu’s STING agonist technology. The company was formerly known as Selvita S.A. and changed its name to Ryvu Therapeutics S.A. in October 2019. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.

Employees
228
Market
Poland

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6.38M27.60%102.21M
Other Institutional Investors
6.58M28.44%105.35M
Public Companies & Retail Investors
10.16M43.96%162.82M
Total
23.12M100.00%370.38M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Towarzystwo Funduszy Inwestycyjnych Allianz Polska S.A.9.87%2,282,90936,572
PTE Allianz Polska SA9.22%2,132,54034,163

People Also Watch

11.5800
LBW
-0.17%
360.00
SNTP
-3.64%
5,415.00
BFT
-0.91%
27.95
SLV1
-0.18%
135.35
ALRR
-0.37%

FAQ

What Is the Ryvu (RVU) Stock Price Today?

The Ryvu stock price today is 16.00 PLN.

What Stock Exchange Does Ryvu Trade On?

Ryvu is listed and trades on the Warsaw Stock Exchange.

What Is the Stock Symbol for Ryvu?

The stock symbol for Ryvu is "RVU."

What Is the Ryvu Market Cap?

As of today, Ryvu market cap is 370.38M PLN.

What Is Ryvu's Earnings Per Share (TTM)?

The Ryvu EPS (TTM) is -3.84.

When Is the Next Ryvu Earnings Date?

Ryvu will release its next earnings report on 10/09/2026.

From a Technical Analysis Perspective, Is RVU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Ryvu Stock Split?

Ryvu has split 0 times.

How Many Employees Does Ryvu Have?

Ryvu has 228 employees.

What is the current trading status of Ryvu (RVU)?

As of 06/08/2026, Ryvu (RVU) is trading at a price of 16.00 PLN, with a previous close of 16.02 PLN. The stock has fluctuated within a day range of 15.80 PLN to 16.30 PLN, while its 52-week range spans from 13.64 PLN to 31.90 PLN.

What Is Ryvu (RVU) Price Target According to Analysts?

The average 12-month price target for Ryvu is 33.62 PLN, with a high estimate of 49.1 PLN and a low estimate of 17 PLN. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +110.12% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.